Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
LIGAND PHARMACEUTICALS INC
Bear Case (25th pct.)
-72.1% vs price
Base Case (Median)
-65.4% vs price
Bull Case (75th pct.)
-61.3% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $57.65 | -81.0% | High (40%) |
| PE Comparable | $216.69 | -28.5% | Medium (25%) |
| Graham Number | $104.92 | -65.4% | Medium (40%) |
| EV/EBITDA | $84.63 | -72.1% | Medium (20%) |
| EV/FCF | $117.24 | -61.3% | Medium (20%) |
Based on 5 out of 7 methods, LGND appears overvalued at the current price of $302.96. The base case fair value of $104.92 implies 65.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.